Table 3.
UK audit |
|
---|---|
(n = 242) | |
Chemotherapy regimen | |
MMC 5-FU | 156 (64.5%) |
MMC capecitabine | 68 (28.1%) |
Cisplatin/5-FU | 3 (1.2%) |
MMC alone | 1 (0.4%) |
5-FU alone | 1 (0.4%) |
Capecitabine alone | 2 (0.8%) |
Cisplatin/Etoposide | 2 (0.8%) |
No chemotherapy | 8 (3.3%) |
Cisplatin alone | 1 (0.4%) |
MMC, mitomycin; 5-FU, 5-fluorouracil.